Latest news

U.S. Food and Drug Administration accepts the submitted Biologic License Application for Coagulation Factor VIIa (Recombinant), activated eptacog beta.

Read More

Contact Medical Affairs

Healthcare professionals, learn more about the science behind HEMA Biologics investigational therapies for the treatment of rare bleeding disorders.

Read More

Join the brigade!

Check out our new app, and become Sergeant Factor in this exciting interactive experience.

Read More

“Our mission is to help improve health and care for people living with
the rarest bleeding disorders.”